A subscription to JoVE is required to view this content. Sign in or start your free trial.
Presented here are two methods that can be used individually or in combination to analyze the effect of beta-amyloid on fibrin clot structure. Included is a protocol for creating an in vitro fibrin clot, followed by clot turbidity and scanning electron microscopy methods.
This article presents methods for generating in vitro fibrin clots and analyzing the effect of beta-amyloid (Aβ) protein on clot formation and structure by spectrometry and scanning electron microscopy (SEM). Aβ, which forms neurotoxic amyloid aggregates in Alzheimer's disease (AD), has been shown to interact with fibrinogen. This Aβ-fibrinogen interaction makes the fibrin clot structurally abnormal and resistant to fibrinolysis. Aβ-induced abnormalities in fibrin clotting may also contribute to cerebrovascular aspects of the AD pathology such as microinfarcts, inflammation, as well as, cerebral amyloid angiopathy (CAA). Given the potentially critical role of neurovascular deficits in AD pathology, developing compounds which can inhibit or lessen the Aβ-fibrinogen interaction has promising therapeutic value. In vitro methods by which fibrin clot formation can be easily and systematically assessed are potentially useful tools for developing therapeutic compounds. Presented here is an optimized protocol for in vitro generation of the fibrin clot, as well as analysis of the effect of Aβ and Aβ-fibrinogen interaction inhibitors. The clot turbidity assay is rapid, highly reproducible and can be used to test multiple conditions simultaneously, allowing for the screening of large numbers of Aβ-fibrinogen inhibitors. Hit compounds from this screening can be further evaluated for their ability to ameliorate Aβ-induced structural abnormalities of the fibrin clot architecture using SEM. The effectiveness of these optimized protocols is demonstrated here using TDI-2760, a recently identified Aβ-fibrinogen interaction inhibitor.
Alzheimer's disease (AD), a neurodegenerative disease leading to cognitive decline in elderly patients, predominately arises from abnormal beta-amyloid (Aβ) expression, aggregation and impaired clearance resulting in neurotoxicity1,2. Despite the well-characterized association between Aβ aggregates and AD3, the precise mechanisms underlying the disease pathology are not well understood4. Increasing evidence suggests that neurovascular deficits play a role in the progression and severity of AD5, as Aβ directly interacts with ....
1. Preparation of Aβ42 and Fibrinogen for Analysis
In the in vitro clotting (turbidity) assay, the enzyme thrombin cleaves fibrinogen, resulting in the formation of the fibrin network24. This fibrin clot formation causes scattering of the light passing through the solution, resulting in increased turbidity (Figure 1), plateauing before the end of the reading period (Figure 2, green). When the fibrinogen was incubated in the presence of Aβ42, .......
The methods described here provide a reproducible and rapid means of assessing fibrin clot formation in vitro. Furthermore, the simplicity of the system makes the interpretation of how Aβ affects the fibrin clot formation and structure relatively straight-forward. In this lab's previous publication, it was shown that these assays can be used to test compounds for their ability to inhibit the Aβ-fibrinogen interaction13,14. Using these two a.......
The authors have nothing to disclose.
Authors thank Masanori Kawasaki, Kazuyoshi Aso, and Michael Foley from Tri-Institutional Therapeutics Discovery Institute (TDI), New York for synthesis of Aβ-fibrinogen interaction inhibitors and their valuable suggestions. Authors also thank members of the Strickland lab for helpful discussion. This work was supported by NIH grant NS104386, the Alzheimer's Drug Discovery Foundation, and Robertson Therapeutic Development Fund for H.A., NIH grant NS50537, the Tri-Institutional Therapeutics Discovery Institute, Alzheimer's Drug Discovery Foundation, Rudin Family Foundation, and John A. Herrmann for S.S.
....Name | Company | Catalog Number | Comments |
Fibriogen, Plasminogen-Depleted, Plasma | EMD Millipore | 341578 | keep lid parafilm wrapped to avoid exposure to moisture |
Beta-Amyloid (1-42), Human | Anaspec | AS-20276 | |
Thrombin from human plasma | Sigma-Aldrich | T7009 | |
1,1,1,3,3,3-Hexafluoro-2-propanol, Greater Than or Equal to 99% | Sigma-Aldrich | 105228 | |
DIMETHYL SULFOXIDE (DMSO), STERILE-FILTERED | Sigma-Aldrich | D2438 | |
Pierce BCA Protein Assay Kit | Thermo Scientific | 23225 | |
Tris Base | Fischer Scientific | BP152 | |
HEPES | Fischer Scientific | BP310 | |
NaCl | Fischer Scientific | S271 | |
CaCl2 | Fischer Scientific | C70 | |
Filter Syringe, 0.2µM, 25mm | Pall | 4612 | |
Millex Sterile Syringe Filters, 0.1 um, PVDF, 33 mm dia. | Millipore | SLVV033RS | |
Solid 96 Well Plates High Binding Certified Flat Bottom | Fischer Scientific | 21377203 | |
Spectramax Plus384 | Molecular Devices | 89212-396 | |
Centrifuge, 5417R | Eppendorf | 5417R | |
Branson 200 Ultrasonic Cleaner | Fischer Scientific | 15-337-22 | |
Lab Rotator | Thermo Scientific | 2314-1CEQ | |
Spare washers for cover slip holder | Tousimis | 8766-01 | |
Narrow Stem Pipets - Sedi-Pet | Electron Microscopy Sciences (EMS) | 70967-13 | |
Sample holder for CPD (Cover slip holder) | Tousimis | 8766 | |
Mount Holder Box, Pin Type | Electron Microscopy Sciences (EMS) | 76610 | |
Round glass cover slides (12 mm) | Hampton Research | HR3-277 | |
10% Glutaraldehyde | Electron Microscopy Sciences (EMS) | 16120 | |
Ethanol | Decon Labs | 11652 | |
24 well plate | Falcon | 3047 | |
Na Cacodylate | Electron Microscopy Sciences (EMS) | 11652 | |
SEM Stubs, Tapered end pin. | Electron Microscopy Sciences (EMS) | 75192 | |
PELCO Tabs, Carbon Conductive Tabs, 12mm OD | Ted Pella | 16084-1 | |
Autosamdri-815 Critical Point Dryer with Gold/Palladium target | Tousimis | ||
Denton Desk IV Coater | Denton Vacuum | ||
Leo 1550 FE-SEM | Carl Zeiss | ||
Smart SEM Software | Carl Zeiss |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved